Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nab-paclitaxel, Nab-Paclitaxel
nab-paclitaxel+ carboplatin · 1 trial · 10 indications
To assess the safety and tolerability profile of first-line chemotherapy in combination with durvalumab + tremelimumab
To assess incidence of Adverse Events for the safety and tolerability profile of first-line chemotherapy in combination with durvalumab and tremelimumab
To estimate the objective response rate (ORR) of durvalumab + tremelimumab + chemotherapy (for cohort 6 only)
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN) |
| Cohort 2 | EXPERIMENTAL | Small-cell lung cancer (SCLC) |
| Cohort 3 | EXPERIMENTAL | Triple-negative breast cancer (TNBC) |
| Cohort 4 | EXPERIMENTAL | Triple-negative breast cancer (TNBC) |
| Cohort 5 | EXPERIMENTAL | Gastric/gastro-esophageal junction (GEJ) |
| Cohort 6 | EXPERIMENTAL | Pancreatic ductal adenocarcinoma (PDAC) |
| Cohort 7 | EXPERIMENTAL | Esophageal squamous cell carcinoma (ESCC) |
| Name | Type | Description |
|---|---|---|
| paclitaxel + carboplatin | DRUG | IV infusion |
| carboplatin + etoposide | DRUG | IV infusion |
| gemcitabine + carboplatin | DRUG | IV infusion |
| nab-paclitaxel (paclitaxel-albumin) + carboplatin | DRUG | IV infusion |
| oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid) | DRUG | IV infusion and bolus administration |
| durvalumab | BIOLOGICAL | IV infusion |
| tremelimumab | BIOLOGICAL | IV infusion |
| nab-paclitaxel (paclitaxel-albumin) + gemcitabine | DRUG | IV infusion |
| cisplatin + 5-fluorouracil (5FU) | DRUG | IV infusion |
Inclusion Criteria: 1. ≥18 years 2. Written informed consent 3. Patients with histologically or cytologically documented chemotherapy-naïve locally advanced unresectable or metastatic ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC, gastric cancer/GEJ, PDAC and ESCC. 4. ECOG performance...
Nab-Paclitaxel is being studied for use in advanced or metastatic breast cancer and small cell lung carcinoma. It is an oncology small molecule being evaluated in combination with other agents as part of clinical trials for these indications.
Nab-Paclitaxel is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials to evaluate the drug in oncology indications.
Nab-Paclitaxel is in Phase 3 clinical development. It is an investigational drug being studied in active clinical trials for advanced or metastatic breast cancer and is not yet approved by regulatory authorities.
Nab-Paclitaxel is part of the Phase 3 trial NCT04494425, which studies trastuzumab deruxtecan versus investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer. This trial has enrolled 866 participants across multiple countries.
Nab-Paclitaxel is also known as Nab-paclitaxel+carboplatin, which refers to the combination regimen being studied. The drug is being evaluated in combination with carboplatin in clinical trials for certain cancers.